Effects of atrial natriuretic peptide on inter-organ crosstalk among the kidney, lung, and heart in a rat model of renal ischemia-reperfusion injury
© Mitaka et al.; licensee Springer. 2014
Received: 5 May 2014
Accepted: 22 October 2014
Published: 8 November 2014
Renal ischemia-reperfusion injury (IRI) is a common cause of acute kidney injury and a frequent occurrence in critically ill patients. Renal IRI releases proinflammatory cytokines within the kidney that induce crosstalk between the kidney and other organ systems. Atrial natriuretic peptide (ANP) has anti-inflammatory as well as natriuretic effects and serves important functions as a regulator of blood pressure, fluid homeostasis, and inflammation. The objective of the present study was to elucidate whether ANP post-treatment attenuates kidney-lung-heart crosstalk in a rat model of renal IRI.
In experiment I, a rat model of unilateral renal IRI with mechanical ventilation was prepared by clamping the left renal pedicle for 30 min. Five minutes after clamping, saline or ANP (0.2 μg/kg/min) was infused. The hemodynamics, arterial blood gases, and plasma concentrations of lactate and potassium were measured at baseline and at 1, 2, and 3 h after declamping. The mRNA expression and localization of tumor necrosis factor (TNF)-α, interleukin (IL)-1β, and IL-6 in the kidney, lung, and heart were examined. In experiment II, a rat model of bilateral renal IRI without mechanical ventilation was prepared by clamping bilateral renal pedicles for 30 min. Thirty minutes after clamping, lactated Ringer's (LR) solution or ANP (0.2 μg/kg/min) was infused. Plasma concentrations of TNF-α, IL-6, and IL-1β were determined at baseline and at 3 h after declamping.
In unilateral IRI rats with mechanical ventilation, ANP inhibited the following changes induced by IRI: metabolic acidosis; pulmonary edema; increases in lactate, creatinine, and potassium; and increases in the mRNA expression of TNF-α, IL-1β, and IL-6 in the kidney and lung and IL-1β and IL-6 in the heart. It also attenuated the histological localization of TNF-α, IL-6, and nuclear factor (NF)-κB in the kidney and lung. In bilateral IRI rats without mechanical ventilation, ANP attenuated the IRI-induced increases of the plasma concentrations of potassium, IL-1β, and IL-6.
Renal IRI induced injury in remote organs including the lung and the contralateral kidney. ANP post-treatment ameliorated injuries in these organs by direct tissue protective effect and anti-inflammatory effects, which potentially inhibited inter-organ crosstalk.
KeywordsAcute kidney injury Atrial natriuretic peptide Cardiorenal syndrome Cytokine Lung inflammation Ischemia-reperfusion Rat
Renal ischemia-reperfusion injury (IRI) is a common cause of acute kidney injury (AKI) in critically ill patients. Critically ill patients with AKI generally receive continuous renal replacement therapy, but the effects are insufficient to spare them from high mortality ,. The high risk of death from AKI stems from extrarenal complications resulting from inter-organ crosstalk and multiple organ dysfunction syndrome ,. Renal IRI exemplifies the pathophysiological significance of increased cytokine levels and enhanced inflammatory responses , that injure and inflame remote organs such as the lung  and heart .
Atrial natriuretic peptide (ANP) has natriuretic, diuretic, and vasodilating properties and serves important functions as a regulator of blood pressure and fluid volume homeostasis . ANP increases the glomerular filtration rate (GFR) by dilating afferent arterioles and constricting efferent arterioles to increase the glomerular capillary hydraulic pressure . It has also been found to enhance recovery from renal IRI by increasing the renal medullary blood flow in rats . In a clinical setting, ANP infusion improves pulmonary capillary wedge pressure and cardiac index in patients with acute heart failure  and preserves renal function after cardiovascular surgery -. ANP has also been found to confer anti-inflammatory effects by inhibiting nuclear factor (NF)-κB activation and cytokine production -. In a recent study by our group, ANP pre-treatment prevented kidney-lung crosstalk in a rat model of renal IRI . Yet it remains unclear whether ANP post-treatment protects the heart as well as lung after renal IRI. We hypothesized that the post-treatment might benefit the kidney, lung, and heart in a general fashion by attenuating inflammation. We divided the experiments into two parts, I and II. Our hypothesis of experiment I is that unilateral renal IRI induces inflammation on the contralateral kidney as well as remote organs and ANP post-treatment attenuates kidney-lung crosstalk by inhibiting expanding inflammation. Therefore, we examined the effects of IRI-induced inflammation on the contralateral kidney, lung, and heart in a rat model of unilateral renal IRI with mechanical ventilation and elucidated whether ANP post-treatment attenuates inter-organ crosstalk among the kidney, lung, and heart by inhibiting inflammation. Further, in experiment II, we adopted a rat model of bilateral renal IRI to bring our model somewhat closer to clinical reality. Our hypothesis of experiment II is that bilateral renal IRI induces kidney injury accompanied by increase in circulating cytokines and ANP post-treatment attenuates release of cytokines from the kidney into circulation. Therefore, we determined plasma cytokine concentration in the rat model of bilateral renal IRI excluding the effects of mechanical ventilation and saline and elucidated the inhibitory effect of ANP post-treatment on spreading inflammation.
All the protocols in this study were approved by the Institutional Animal Care Committee of Tokyo Medical and Dental University (0140245A).
The animals were handled and cared for in accordance with the National Institutes of Health guidelines. Thirty-four male Sprague-Dawley rats (body weight 254 to 311 g) were anesthetized with an intraperitoneal injection of pentobarbital sodium (5 mg/100 g body weight). Each animal underwent a tracheostomy and intratracheal cannulation and was mechanically ventilated (Respirator Model SN-480-7, Shinano Ltd., Tokyo, Japan) under the following conditions: FIO2 0.21, tidal volume of 10 ml/kg with 5 cmH2O positive end-expiratory pressure, respiratory rate of 30 to 40 cycles/min. The right carotid artery was cannulated with a catheter for continuous measurement of the arterial pressure and heart rate and for intermittent arterial blood sampling. The arterial pressure was measured with a blood pressure amplifier (AP-641G, SEN-6102M, Nihon Kohden, Tokyo, Japan) and data acquisition system (PowerLab2/26, ML826, ADInstruments, Bella Vista, Australia) by connecting the catheter to a transducer and calibrating at zero at the midchest. The right femoral vein was cannulated with a catheter for infusion of saline or ANP. The ANP was a generous gift from the Daiichi Sankyo Company (Tokyo, Japan).
The left renal pedicle was exposed via a midline incision, clamped with a vascular clip for 30 min, and released. Occlusion was verified visually by the change in the color of the kidney to a paler hue. After clamp removal, the restoration of the blood flow to the kidney was confirmed upon the return of the original color. The abdomen was closed in one layer. The sham surgery consisted of the same procedure, but with no clamping of the left renal pedicle. This renal ischemia-reperfusion injury is a model of AKI.
The rats were randomized to four experimental groups: an 1) IRI + saline group (n = 10), 2) IRI + ANP group (n = 10), 3) sham + saline group (n = 6), and 4) sham + ANP group (n = 8). All of the animals were mechanically ventilated. From 5 min after clamping of the left renal pedicle, the IRI + saline and sham + saline groups were infused with saline for 3 h 25 min at a rate of 6 ml/kg/h. The ANP infusion in the IRI + ANP and saline + ANP groups was started at the same time point (from 5 min after clamping of the left renal pedicle) and administered at the same rate and duration (0.2 μg/kg/min for 3 h 25 min) using saline mixed with ANP dissolved in 2-ml portions of distilled water. The heart rate, mean arterial pressure, arterial blood gases, and plasma concentrations of lactate, creatinine, and potassium were measured at baseline and at 1, 2, and 3 h after declamping. Blood gas analysis was performed on a blood gas analyzer (Radiometer ABL 837, Radiometer Medical ApS, Copenhagen, Denmark). At the completion of the experiment, all of the animals were killed with overdose of pentobarbital. The kidney, lung, and heart were harvested and either preserved at −80°C until use for the cytokine mRNA analysis or preserved in formalin until the histologic examination.
Wet/dry ratio of the lung
The wet/dry ratio of the lung is a gravimetric measure of pulmonary edema and an accurate gauge of changes in the lung dry mass . We measured the wet/dry ratio by the same method reported by Heremans et al.  by desiccating the lung at 80°C until a constant weight was obtained. The ratio was calculated as a parameter of lung edema.
RNA extraction and TaqMan real-time PCR
Total RNA was extracted from the kidney, lung, and heart with TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. The RNA concentration was determined by the absorbance read at 260 nm (GeneQuant 100, GE Healthcare UK Ltd, Chalfont St Giles, Buckinghamshire, UK). The primers and TaqMan probes for tumor necrosis factor (TNF)-α, interleukin (IL)-1β, IL-6, and glutaraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA were purchased from a commercial laboratory (Applied Biosystems, Foster City, CA, USA). The mRNA expressions of TNF-α, IL-1β, and IL-6 were determined by real-time polymerase chain reaction (PCR). cDNA was synthesized using TaqMan reverse transcription reagents (Applied Biosystems, Roche Molecular Systems, Inc., Branchburg, NJ, USA) and quantified using a thermal cycler (PC707, ASTEC Co., Ltd., Minato-ku, Japan). TaqMan real-time PCR was performed using an ABI 7900HT (Applied Biosystems, Foster City, CA, USA). TaqMan rat GAPDH was used as an internal control and relative gene expression values were determined using the 2−ΔΔCT method .
TNF-α, IL-6, and NF-κB immunostaining and scoring in the kidney, lung, and heart
Five rats from each group were used for the immunohistochemical examination. The kidney, lung, and heart were resected, embedded in paraffin, sliced into thin sections, and immunostained. Anti-TNF-α goat polyclonal antibody (SC-1348, diluted 1:20) and anti-IL-6 rabbit polyclonal antibody (SC-1265-R, diluted 1:200) were purchased from Santa Cruz Biotechnology (Dallas, TX, USA). Anti-NF-κB rabbit monoclonal antibody (1559-1, clone E381, diluted 1:200) was purchased from Epitomics (Burlingame, CA, USA). The sections were deparaffinized with xylene. For the IL-6 immunostaining, the sections were heat-treated in a microwave oven in citric acid buffer at pH 6.0 for 20 min and then air-cooled for 20 min. For the TNF-α and NF-κB immunostaining, the heat treatment was omitted. The subsequent immunostaining procedure was commenced by rehydrating the sections with an alcohol series and then treating them for 10 min with dH2O and H2O2 to inactivate the endogenous peroxidase. The antibodies were then added to the sections in a moisture chamber and reacted at RT for 3 h. After washing in phosphate buffer solution with Tween20 (PBST) for 30 min, the TNF-α samples were reacted for 30 min by indirect immunostaining using anti-goat antibody conjugated with horseradish peroxidase (P0449, diluted 1:30, DAKO, Tokyo, Japan). The IL-6 and NF-κB samples were visualized using a Novo Link Polymer Kit (RE7280-K, Leica Microsystems, Tokyo, Japan). After reacting the linker and polymer in the kit for 30 min each, the slides were visualized with diaminobenzidine, counterstained with hematoxylin, dehydrated, and cover-slipped. TNF-α, IL-6, and NF-κB expressions were evaluated semi-quantitatively by randomly choosing five areas in each slide and having them uniformly evaluated in a high-power field (×200) by a pathologist who had no knowledge of the experimental conditions (one of the authors). Scores of 3, 2, 1, and 0 were respectively assigned to fields with strong, moderate, weak, and negligible staining for each immunostaining. The level of expression was the mean value of five fields (TNF-α, IL-6, and NF-κB expression score, respectively).
Thirteen male Sprague-Dawley rats (body weight 327 to 376 g) were anesthetized with an intraperitoneal injection of pentobarbital sodium (5 mg/100 g body weight). Each animal was allowed to breathe spontaneously, without mechanical ventilation. The right carotid artery was cannulated with a catheter and the arterial pressure was measured with a blood pressure amplifier as stated above. The right femoral vein was cannulated with a catheter for infusion of lactated Ringer's (LR) solution or ANP. The bilateral renal pedicles were clamped with vascular clips for 30 min and released. The rats were randomized to three groups: 1) IRI + LR group (n = 5), 2) IRI + ANP group (n = 5), and 3) sham + LR group (n = 3). From 30 min after clamping, the IRI + LR and sham + LR groups were infused with LR for 3 h at a rate of 6 ml/kg/h. The ANP infusion in the IRI + ANP group was started at the same time point and administered at the same rate and for the same duration (0.2 μg/kg/min for 3 h) using LR mixed with ANP dissolved in 2-ml portions of distilled water. The heart rate, mean arterial pressure, arterial blood gases, and plasma concentrations of lactate, creatinine, and potassium were measured at baseline and at 1, 2, and 3 h after declamping. The plasma concentrations of TNF-α, IL-1β, and IL-6 were determined at baseline and at 3 h using the rat ELISA kit (Quantikinetm TM, R&D Systems, Minneapolis, MN, USA) following the manufacturer's instruction. The samples were tested in duplicate.
All data are shown as median and interquartile range (IQR). The hemodynamics; plasma concentrations of creatinine, lactate, potassium, and cytokines; and blood gas variables were all analyzed by the Kruskal-Wallis test at a fixed time point (3 h after declamping), as notable time-dependent changes in these parameters were found in repeated measures ANOVA for all three groups. The Kruskal-Wallis test was used to compare the wet/dry ratio, cytokine mRNA expression, and TNF-α, IL-6, and NF-κB scoring among the four groups. If the result from the Kruskal-Wallis test was significant, then the Mann-Whitney U test was similarly applied to analyze each pairing of groups. A p value of less than 0.05 was considered statistically significant.
Changes in hemodynamic variables and plasma concentrations of creatinine and potassium
Changes in arterial blood gas variables, plasma lactate concentration, and lung wet/dry ratio
Cytokine mRNA expression in the kidney, lung, and heart
Histological detection and localization of TNF-α, IL-6, and NF-κB in the kidney, lung, and heart
The most compelling findings observed in this rat model of unilateral renal IRI with mechanical ventilation (experiment I) were that unilateral renal IRI induced inflammation not only in the ipsilateral kidney but also in remote organs including the contralateral kidney, lung, and heart and ANP post-treatment inhibited inflammation of these organs. In addition, ANP post-treatment inhibited the renal IRI-induced metabolic acidosis, pulmonary edema, and increases in the plasma concentrations of lactate, creatinine, and potassium. Although unilateral renal IRI is not the main cause of AKI in critically ill patients, unilateral renal IRI remains a major problem in surgeries, such as renal transplantation  and juxtarenal and suprarenal abdominal aortic aneurysm repair . The renal function of these patients must be preserved during the perioperative period. We therefore tried to investigate the effects of unilateral renal IRI on the non-ischemic contralateral kidney, as well as the lung and heart. Renal IRI augmented the mRNA expressions of TNF-α, IL-1β, and IL-6 in the kidney and lung, and this effect was inhibited by the ANP post-treatment. Renal IRI also augmented the mRNA expression of IL-1β and IL-6 in the heart, and the ANP post-treatment again inhibited the augmenting action. The ANP post-treatment prevented the renal IRI-induced localization of TNF-α, IL-6, and NF-κB in the kidney and IL-6 and NF-κB in the lung. Furthermore, in experiment II, the bilateral renal IRI increased the plasma concentrations of IL-1β and IL-6, but not the concentration of TNF-α, and the ANP treatment 30 min after clamping attenuated the increases in IL-1β and IL-6. The plasma TNF-α concentration might have passed its peak at 3 h. These results corroborate earlier evidence of an ANP-conferred enhancement of recovery from renal IRI in rats  and strengthen evidence favoring ANP as a possible treatment for AKI. In an earlier study by our group, ANP preserved renal function after suprarenal abdominal aortic cross-clamping in a dog model approximating ischemic AKI following abdominal aortic aneurysm repair . In clinical studies, low-dose ANP infusion after cardiovascular surgery enhanced the renal excretory function, decreased the probability of dialysis, and improved the dialysis-free survival in ischemic acute renal failure -. The induction of IRI in the present study led to reduction in MAP in the saline group and LR group, but not in the sham group or ANP group. The plasma lactate concentration was also found to increase sharply in the IRI + saline group, but no such increase was observed after ANP treatment. These findings suggest that the administration of ANP might contribute to prevention of extravasation of the fluid, which resulted in maintenance of peripheral circulation. Our results showed successful results of ANP post-treatment in attenuating renal IRI and reducing cytokine mRNA expression in the kidney, lung, and heart. ANP post-treatment also reduced plasma cytokine (IL-1β and IL-6) concentrations, and this might be one of the mechanisms explaining the therapeutic effect of ANP on remote organ inflammation.
Renal IRI generally leads to outer medullary congestion and hypoxia, conditions that predispose patients to ischemic injury in the S3 segment of the proximal tubule . ANP increases GFR by dilating the afferent arterioles and constricting the efferent arterioles to increase glomerular capillary hydraulic pressure . The reno-protective effect of ANP may derive from protection against medullary ischemia via ANP-induced increases in the medullary vasa recta blood flow ,.
Renal IRI and inflammation of remote organs
Renal IRI engages the innate and adaptive immune responses and works in conjunction with cytokine generation within the kidney . Once this process starts, cellular and soluble mediators injure remote organs such as the lung and heart via organ crosstalk.
Renal IRI induced lung inflammation in a mouse model with systemic inflammatory syndrome and upregulated IL-6 mRNA expression in both the kidney and lung . These findings are consistent with our present results. After renal IRI, we also detected and localized IL-6 in the columnar epithelial cells of the bronchioles of the lung and the vascular endothelial cells and proximal convoluted tubules of the kidney in our animals.
The alveolar epithelium has features in common with the renal tubular epithelium, such as localization of water channels and ion transporters . Mechanisms of renal IRI-induced lung injury are assumed to include a dysregulation of water clearance, inflammation, an innate immune response, proinflammatory cytokines, oxidative stress, and apoptosis .
Studies confirming the expression of ANP and its receptors and their variable modes of regulation in the immune system  support the notion that ANP has immunomodulatory potency. ANP inhibits the activation of NF-κB production in both mouse macrophages and endothelial cells -. ANP post-treatment of our experimental animals inhibited the mRNA expression of TNF-α, IL-1β, and IL-6 in the kidney. The ability of ANP to suppress the induction of proinflammatory cytokines such as TNF-α, IL-1β, and IL-6 may signify a substantive anti-inflammatory action on the kidney and lung. ANP post-treatment was also found to inhibit the activation of NF-κB production in the kidney and lung in our study. These findings suggest that ANP has anti-inflammatory effects on both organs.
Increased capillary endothelial permeability is a major pathologic mechanism of pulmonary edema in acute lung injury and acute respiratory distress syndrome. Our group previously reported that ANP improved pulmonary gas exchange by reducing extravascular lung water in patients with acute lung injury  and in a canine model with oleic acid-induced pulmonary edema . This finding is corroborated by reports that ANP knockout in mice increases the severity of lung inflammation and vascular barrier dysfunction caused by bacterial pathogens ,. Increased ANP levels in patients with acute lung injury  may represent an important compensatory mechanism aimed at attenuation of injury and lung barrier dysfunction. Tian et al.  recently demonstrated a novel protective mechanism of ANP against pathologic hyper-permeability and suggested a pharmacological intervention for the prevention of increased vascular leak via PAK1-dependent modulation of guanine nucleotide exchange factor H1 activity. The activity of renal NF-κB appears to increase in the absence of the functional guanylyl cyclase/natriuretic peptide receptor-A (GC-A/NPRA) gene 1 and to elicit abnormalities by stimulating the synthesis of proinflammatory cytokines . These findings, taken together, show that ANP protects the kidney by preventing proinflammatory cytokines via conterregulatory effects on NF-κB signaling.
Several inflammatory mediators participate in the pathophysiologic process of cardiorenal syndrome . Increased production of inflammatory cytokines may adversely affect myocardial function. Elevated levels of circulating TNF-α and IL-6 are associated with the development of congestive heart failure and mortality in congestive heart failure patients ,. Several different pathways, most notably the activation of inflammatory transcription factors and the induction of inflammatory genes and cytokines, may contribute to heart injury following renal IRI.
Renal IRI induced the mRNA expressions of TNF-α, IL-1β, and IL-6 in the heart, in our experiments, and ANP post-treatment attenuated the mRNA expressions of the latter two, IL-1β and IL-6. Yet the localizations of TNF-α, IL-6, and NF-κB in the heart at 3 h in the IRI + saline group were not significantly increased or significantly different from the localizations in other groups. These findings suggest that the cardiac levels of TNF-α, IL-6, and NF-κB were not increased in the heart 3 h after renal IRI. It may take more than 3 h to increase the cardiac levels of cytokines and NF-κB. In experiments with a rat model of renal IRI, Kelly  demonstrated an increase of circulating TNF-α by 1 h post renal ischemia, a further increase at 2 h, and steady elevation of the cytokine for 24 h. The cardiac levels of immnoreactive IL-1 and TNF-α in the same animals were elevated at 6, 24, and 48 h after renal ischemia, and echocardiography revealed left ventricular dysfunction, a likely sign of heart failure, at 48 h after renal IRI. It may take a longer time for renal IRI to induce hear failure.
Inhibition of inter-organ crosstalk by ANP
It may be difficult to differentiate between inhibition of inter-organ crosstalk and direct organ protection, given that ANP has now been shown to confer protective effects on other organs in addition to the established anti-inflammatory effects. We know, however, that inter-organ crosstalk develops via cellular mediators such as neutrophils, macrophages, and lymphocytes, and inflammatory cytokines . Matsumura et al.  have reported that ANP modulates the neutrophil functions and exerts protective effects against the neutrophil-induced endothelial cytotoxity. Chujo et al.  have also shown that ANP significantly inhibits IRI-induced increases in renal cytokine-induced neutrophil chemoattractant-1, a chemokine responsible for the activation of neutrophils and for neutrophil chemotaxis to sites of injury. Regarding plasma cytokine concentration which would be the main route of expansion of inflammation, ANP post-treatment attenuated IRI-induced elevation of the plasma concentrations of IL-1β and IL-6. We therefore suppose that ANP may both directly and indirectly disrupt the inter-organ crosstalk following renal IRI.
Limitations of this study
There are some limitations to this study. First, in the present study, we have evaluated the effects of ANP on only renal IRI. Considering that there are multiple causes of AKI in critically ill patients (e.g., sepsis, nephrotoxic agents, hypoperfusion, and their combination) other than IRI, we cannot refer to the effects of ANP on AKI caused by other mechanisms. However, because it was notable that ANP post-treatment was effective to reduce tissue injury in the lung and kidney both in unilateral and in bilateral renal IRI, further study is needed to elucidate whether this beneficial effect might be observed in other pathophysiologic conditions. Second, saline infusion and mechanical ventilation might be an aggravating factor for organ injury in the present study. Unilateral renal IRI (experiment I) with mechanical ventilation induced significant metabolic acidosis. This result may have been due to a decrease in the renal blood flow by the positive pressure ventilation. Further, the applied tidal volume of 10 ml/kg might be a little too high to protect against lung injury. Bilateral renal IRI without mechanical ventilation (experiment II) did not induce acidosis by respiratory compensation, and the arterial blood gas bicarbonate was maintained by the infusion of LR. These findings suggest that the mechanical ventilation and saline both worsened the arterial blood gas parameters after the renal IRI. A recent clinical study has actually shown chloride-restrictive fluid infusion to be significantly associated with a significant decreased incidence of AKI and a significantly decreased use of renal replacement therapy in critically ill patients . Therefore, we should consider the possibility that mechanical ventilation per se, ventilator setting, and type of infusion become exacerbation factors for organ dysfunction after the renal IRI. Nevertheless, it is noteworthy that ANP post-treatment has clearly prevented IRI-induced remote organ inflammation even in the condition with these kinds of aggravating factors.
Unilateral renal IRI with mechanical ventilation induced inflammation not only in the ipsilateral kidney but also in remote organs including the contralateral kidney, lung, and heart. ANP post-treatment inhibited renal IRI-induced metabolic acidosis and the mRNA expression of TNF-α, IL-1β, and IL-6 in the kidney and lung and IL-1β and IL-6 in the heart. In addition, ANP post-treatment attenuated the IRI-induced increases in the plasma concentrations of IL-1β and IL-6, as well as the IRI-induced histological localization of TNF-α, IL-6, and NF-κB in the kidney and lung. These findings show that ANP conferred a reno-protective effect and anti-inflammatory effect both on the kidney and on the lung in the rat model of renal IRI. The cardiac levels of TNF-α, IL-6, and NF-κB were not significantly increased at 3 h after renal IRI, suggesting that renal IRI-induced heart injury may occur later than lung injury. Further studies are needed to elucidate the anti-inflammatory effects of ANP on the heart.
acute kidney injury
atrial natriuretic peptide
glomerular filtration rate
tumor necrosis factor-α
We thank Dr. Koji Kido for the technical assistance. This study was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (22592010).
- Fuchs L, Joon L, Novack V, Baumfeld Y, Scott D, Celi L, Mandelbaum T, Howell M, Talmor D: Severity of acute kidney injury and two-year outcomes in critically ill patients. Chest 2013, 144: 866–875. 10.1378/chest.12-2967View ArticleGoogle Scholar
- Mehta RL, Pascual MT, Soroko S, Savage BR, Himmerlfarb J, Ikizler TA, Paganini EP, Chertoe GM: Spectrum of acute renal failure in the intensive care unit: the PICARD experience. Kidney Int 2004, 66: 1613–1621. 10.1111/j.1523-1755.2004.00927.xView ArticleGoogle Scholar
- Vieira JM Jr, Castro I, Curvello-Neto A, Demarzo S, Caruso P, Pastore L Jr, Imanishe MH, Abdulkader RC, Deheinzelin D: Effect of acute kidney injury on weaning from mechanical ventilation in critically ill patients. Crit Care Med 2007, 35: 184–191. 10.1097/01.CCM.0000249828.81705.65View ArticleGoogle Scholar
- Thurman JM: Triggers of inflammation after renal ischemia/reperfusion. Clin Immunol 2007, 123: 7–13. 10.1016/j.clim.2006.09.008PubMed CentralView ArticleGoogle Scholar
- Kinsky GR, Okusa MD: Pathogenesis of acute kidney injury: foundation for clinical practice. Am J Kid Dis 2011, 58: 291–301. 10.1053/j.ajkd.2011.02.385View ArticleGoogle Scholar
- Campanholle G, Landgraf RG, Gonçalves GM, Paiva VN, Martins JO, Wang PHM, Monteiro RMM, Silva RC, Cenedeze MA, Teixeira VPA, Reis MA, Pacheco-Silva A, Jancar S, Camara NO: Lung inflammation is induced by renal ischemia and reperfusion injury as part of the systemic inflammatory syndrome. Inflamm Res 2010, 59: 861–869. 10.1007/s00011-010-0198-0View ArticleGoogle Scholar
- Kelly KJ: Distant effects of experimental renal ischemia/reperfusion injury. J Am Soc Nephrol 2003, 14: 1549–1558. 10.1097/01.ASN.0000064946.94590.46View ArticleGoogle Scholar
- Levin ER, Gardner DG, Samson WK: Natriuretic peptides. N Engl J Med 1998, 339: 321–328. 10.1056/NEJM199807303390507View ArticleGoogle Scholar
- Marin-Grez M, Fleming JT, Steinhausen M: Atrial natriuretic peptide causes pre-glomerular vasodilation and post-glomerular vasoconstriction in rat kidney. Nature 1986, 324: 473–476. 10.1038/324473a0View ArticleGoogle Scholar
- Chujo K, Ueno M, Asaga T, Sakamoto H, Shirakami G, Ueki M: Atrial natriuretic peptide enhances recovery from ischemia/reperfusion-induced renal injury in rats. J Biosci Bioeng 2010, 109: 526–530. 10.1016/j.jbiosc.2009.11.021View ArticleGoogle Scholar
- Kobayashi D, Yamaguchi N, Takahashi O, Deshpande G, Fukui T: Human atrial natriuretic peptide treatment for acute heart failure: a systemic review of efficacy and mortality. Can J Cardiol 2012, 28: 102–109. 10.1016/j.cjca.2011.04.011View ArticleGoogle Scholar
- Swärd K, Valsson F, Odencrants P, Samuelsson O, Ricksten SE: Recombinant human atrial natriuretic peptide in ischemic acute renal failure: a randomized placebo-controlled trial. Crit Care Med 2004, 32: 1310–1315. 10.1097/01.CCM.0000128560.57111.CDView ArticleGoogle Scholar
- Mitaka C, Kudo T, Jibiki M, Sugano N, Inoue Y, Makita K, Imai T: Effects of human atrial natriuretic peptide on renal function in patients undergoing abdominal aortic aneurysm repair. Crit Care Med 2008, 36: 745–751. 10.1097/CCM.0B013E3181659118View ArticleGoogle Scholar
- Sezai A, Hata M, Niino T, Yoshitaka I, Unosawa S, Wakui S, Kimura H, Shiono M, Takayama T, Hirayama A: Results of low-dose human atrial natriuretic peptide infusion in nondialysis patients with chronic kidney disease undergoing coronary artery bypass grafting. J Am Coll Cardiol 2011, 58: 897–903. 10.1016/j.jacc.2011.03.056View ArticleGoogle Scholar
- Kiemer AK, Hartung T, Vollmar AM: cGMP-mediated inhibition of TNF-α production by the atrial natriuretic peptide in murine macrophages. J Immunol 2000, 165: 175–181. 10.4049/jimmunol.165.1.175View ArticleGoogle Scholar
- Kiemer AK, Weber NC, Fürst R, Bildner N, Kulhanek-Heinze S, Vollmar AM: Inhibition of p38 MARK activation via induction of MKP-1: atrial natriuretic peptide reduces TNF-α-induced actin polymerization and endothelial permeability. Circ Res 2002, 90: 874–881. 10.1161/01.RES.0000017068.58856.F3View ArticleGoogle Scholar
- Ladetzki-Baehs K, Keller M, Kiemer AK, Koch E, Zahler S, Wendel A, Vollmar AM: Atrial natriuretic peptide, a regulator of nuclear factor-κB activation in vivo. Endocrinology 2007, 148: 332–336. 10.1210/en.2006-0935View ArticleGoogle Scholar
- Tulafu M, Mitaka C, Hnin Si MK, Abe S, Kitagawa M, Ikeda S, Eishi Y, Kurata S, Tomita M: Atrial natriuretic peptide attenuates kidney-lung crosstalk in kidney injury. J Surg Res 2014, 186: 217–225. 10.1016/j.jss.2013.07.033View ArticleGoogle Scholar
- Parker JC, Townsley MI: Evaluation of lung injury in rats and mice. Am J Physiol lung Cell Mol Physiol 2004, 286: L231-L246. 10.1152/ajplung.00049.2003View ArticleGoogle Scholar
- Heremans H, Dillen C, Groenen M, Matthys P, Billiau A: Role of interferon-γ and nitric oxide in pulmonary edema and death induced by lipopolysaccharide. Am J Respir Crit Care Med 2000, 161: 110–117. 10.1164/ajrccm.161.1.9902089View ArticleGoogle Scholar
- Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2T-ΔΔC method. Methods 25:402–408Google Scholar
- Menke J, Sollinger D, Schamberger B, Heemann U, Lutz J: The effect of ischemia/reperfusion on the kidney. Curr Opin Organ Transplant 2014, 19: 395–400. 10.1097/MOT.0000000000000090View ArticleGoogle Scholar
- Giulini SM, Bonardelli S, Portolani N, Giovanetti M, Galvani G, Maffeis R, Coniglio A, Tiberio GAM, Nodari F, De Lucia M, Lussardi L, Regina P, Scolari F, Tomasoni G: Suprarenal aortic cross-clamping in elective abdominal aortic aneurysm surgery. Eur J Vas Endovasc Surg 2000, 20: 286–289. 10.1053/ejvs.2000.1171View ArticleGoogle Scholar
- Mitaka C, Hirata Y, Habuka K, Narumi Y, Yokoyama K, Makita K, Imai T: Atrial natriuretic peptide infusion improves ischemic renal failure after suprarenal abdominal aortic cross-clamping in-dogs. Crit Care Med 2003, 31: 2205–2210. 10.1097/01.CCM.0000080487.20304.2EView ArticleGoogle Scholar
- Schrier RW, Wang W, Poole B, Mitra A: Acute renal failure: definitions, diagnosis, pathogenesis, and therapy. J Clin Invest 2004, 114: 5–14. 10.1172/JCI200422353PubMed CentralView ArticleGoogle Scholar
- Kiberd BA, Larson TS, Robertson CR, Jamison RL: Effect of atrial natriuretic peptide on vasa recta blood flow in the rat. Am J Physiol 1987, 252: F1112-F1117.Google Scholar
- Jang HR, Ko GJ, Wasowska BA, Rabb H: The interaction between ischemia-reperfusion and immune responses in the kidney. J Mol Med 2009, 87: 859–864. 10.1007/s00109-009-0491-yView ArticleGoogle Scholar
- Doi K, Ishizu T, Fujita T, Norii E: Lung injury following acute kidney injury: kidney-lung crosstalk. Clin Exp Nephrol 2011, 15: 464–470. 10.1007/s10157-011-0459-4View ArticleGoogle Scholar
- Ko GJ, Rabb H, Hassoun HT: Kidney-lung crosstalk in the critically ill patient. Blood Purif 2009, 28: 75–83. 10.1159/000218087PubMed CentralView ArticleGoogle Scholar
- Vollmar AM, Schmidt KN, Schulz R: Natriuretic peptide receptors on rat thymocytes: inhibition of proliferation by atrial natriuretic peptide. Endocrinology 1996, 137: 1706–1713.Google Scholar
- Mitaka C, Hirata Y, Nagura T, Tsunoda Y, Amaha K: Beneficial effect of atrial natriuretic peptide on pulmonary gas exchange in patients with acute lung injury. Chest 1998, 114: 223–228. 10.1378/chest.114.1.223View ArticleGoogle Scholar
- Mitaka C, Hirata Y, Habuka K, Narumi Y, Yokoyama K, Makita K, Imai T: Atrial natriuretic peptide improves pulmonary gas exchange by reducing extravascular lung water in canine model with oleic acid-induced pulmonary edema. Crit Care Med 2002, 30: 1570–1575. 10.1097/00003246-200207000-00029View ArticleGoogle Scholar
- Birukova AA, Xing J, Fu P, Yakubov B, Dubrovskyi O, Fortune JA, Klibanov AM, Birukov KG: Atrial natriuretic peptide attenuates LPS-induced lung vascular leak: role of PAK1. Am J Physiol Lung Cell Mol Physiol 2010, 299: L652-L663. 10.1152/ajplung.00202.2009PubMed CentralView ArticleGoogle Scholar
- Xing J, Moldobaeva N, Birukova AA: Atrial natriuretic peptide protects against Staphylococcus aureus -induced lung injury and endothelial barrier dysfunction. J Appl Physiol 2011, 110: 213–224. 10.1152/japplphysiol.00284.2010PubMed CentralView ArticleGoogle Scholar
- Mitaka C, Hirata Y, Nagura T, Sakanishi N, Tsunoda Y, Amaha K: Plasma alpha-human atrial natriuretic peptide concentration in patients with acute lung injury. Am Rev Respir Dis 1992, 148: 43–46. 10.1164/ajrccm/146.1.43View ArticleGoogle Scholar
- Tian X, Tian Y, Gawlak G, Sarich N, Wu T, Birukova AA: Control of vascular permeability by atrial natriuretic peptide via guanine nucleotide exchange factor H1 (GEF-H1)-dependent mechanism. J Biol Chem 2014, 289: 5168–5183. 10.1074/jbc.M113.493924PubMed CentralView ArticleGoogle Scholar
- Das S, Periyasamy R, Pandey KN: Activation of IKK/NF-κB provokes renal inflammatory responses in guanylyl cyclase/natriuretic peptide receptor-A gene-knockout mice. Physiol Genomics 2012, 44: 430–442. 10.1152/physiolgenomics.00147.2011PubMed CentralView ArticleGoogle Scholar
- Schrier RW: Role of diminished renal function in cardiovascular mortality: marker or pathogenetic factor? J Am Coll Cardiol 2006, 47: 1–8. 10.1016/j.jacc.2005.07.067View ArticleGoogle Scholar
- Vasan RS, Sullivan LM, Roubenoff R, Dinarello CA, Harris T, Benjamin EJ, Sawyer DB, Levy D, Willson PWF, D'Agostini RB: Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. Circulation 2003, 107: 1486–1491. 10.1161/01.CIR.0000057810.48709.F6View ArticleGoogle Scholar
- Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL: Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST). Circulation 2001, 103: 2055–2059. 10.1161/01.CIR.103.16.2055View ArticleGoogle Scholar
- Matsumura T, Kugiyama K, Suglyama S, Ohgushi M, Yamanaka K, Suzuki M, Yasue H: Neutral endopeptidase 24.11 neutrophils modulates effects of natriuretic peptide against neutrophils-induced endothelial cytotoxity. J Clin Invest 1996, 97: 2192–2203. 10.1172/JCI118660PubMed CentralView ArticleGoogle Scholar
- Chujo K, Ueki M, Asaga T, Taie S: Atrial natriuretic peptide attenuates ischemic/reperfusion-induced renal injury by reducing neutrophil activation in rats. Tohoku J Exp Med 2008, 215: 257–266. 10.1620/tjem.215.257View ArticleGoogle Scholar
- Yunos NM, Bellomo R, Hegarty C, Story D, Ho L, Bailey M: Association between a chloride-liberal vs chloride-restrictive intravenous fluid administration strategy and kidney injury in critically ill adults. JAMA 2012, 308: 1566–1572. 10.1001/jama.2012.13356View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.